Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer

Clin Colorectal Cancer. 2018 Sep;17(3):179-186. doi: 10.1016/j.clcc.2018.03.004. Epub 2018 Mar 8.

Abstract

Introduction: In studies of colorectal cancer, the elderly have been frequently underrepresented because comorbid conditions and functional status often lead to study exclusion. For elderly patients with an indication for neoadjuvant chemoradiotherapy (nCRT), physicians usually decide using clinical factors whether nCRT should be offered. The aim of the present retrospective study was to assess the tolerability of nCRT with capecitabine and the surgical outcomes in patients aged ≥ 70 years with locally advanced rectal cancer.

Patients and methods: Data from 1372 rectal cancer patients diagnosed from 2002 to 2012 at 4 Dutch hospitals were used. Patients aged ≥ 70 years were included if they had received nCRT, and their data were analyzed for treatment deviations, postoperative complications, mortality, disease-free survival (DFS), and overall survival (OS). The data were stratified into 3 age groups (ie, 70-74, 75-79, and ≥ 80 years).

Results: We identified 447 patients aged ≥ 70 years. Of these patients, 42 had received nCRT, and 37 (88%) had completed nCRT. Radiation dermatitis, fatigue, and diarrhea were reported in 62%, 57%, and 43% of the 42 patients, respectively. Of the 42 patients, 40 (95%) underwent surgery, 1 patient refused resection, and 1 patient died during nCRT of severe mucositis due to dihydropyrimidine dehydrogenase deficiency. The postoperative complication rate was 30%, and the 30-day mortality rate was 0%. A pathologic complete response was found in 7.5%. The 2- and 5-year DFS and OS rates were 58.5% and 40.7% and 81.0% and 58.2%, respectively.

Conclusion: The results of the present multicenter study have shown that if selected on clinical factors, nCRT with capecitabine is safe and well tolerated in elderly patients. No negative effect on surgical outcome was measured, and the beneficial effect (pathologic complete response, DFS, and OS) seemed comparable to that for younger age groups. We believe that elderly patients should not be excluded from nCRT on the basis of age only.

Keywords: Elderly patients; LARC; Preoperative chemoradiotherapy; Survival; nCRT.

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Capecitabine / adverse effects*
  • Chemoradiotherapy / adverse effects*
  • Chemoradiotherapy / methods
  • Diarrhea / epidemiology
  • Diarrhea / etiology
  • Disease-Free Survival
  • Fatigue / epidemiology
  • Fatigue / etiology
  • Female
  • Humans
  • Male
  • Neoadjuvant Therapy / adverse effects
  • Neoadjuvant Therapy / methods
  • Neoplasm Staging
  • Netherlands / epidemiology
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Proctectomy / adverse effects
  • Radiodermatitis / epidemiology
  • Radiodermatitis / etiology
  • Rectal Neoplasms / mortality
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / therapy*
  • Rectum / pathology
  • Rectum / surgery
  • Retrospective Studies
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Capecitabine